Key Highlights
- First-quarter adjusted EPS reached $2.57, significantly exceeding Wall Street’s $2.18 projection, representing the company’s fifth consecutive earnings beat
- Quarterly revenue totaled $100.4 billion, substantially surpassing the consensus estimate of $95 billion
- Aetna’s medical benefit ratio dropped to 84.6%, improving from 87.3% in the prior-year period
- Company upgraded 2026 full-year adjusted EPS forecast to $7.30–$7.50 range, increasing from prior $7.00–$7.20 guidance
- Shares rallied 4.9% during premarket hours following the earnings announcement
CVS Health shares soared 4.9% in early Wednesday trading after delivering impressive first-quarter results and upgrading its annual financial outlook.
The healthcare giant reported adjusted earnings of $2.57 per share, significantly surpassing analyst expectations of $2.18. Quarterly revenue reached $100.4 billion, comfortably exceeding Wall Street’s $95 billion projection.
This performance represents the company’s fifth consecutive quarter of beating earnings estimates. CVS has maintained conservative guidance throughout its ongoing transformation efforts following challenges experienced in 2024.
Management elevated its 2026 full-year adjusted EPS projection to a $7.30 to $7.50 range, up from the previous $7.00 to $7.20 forecast. Additionally, the company increased its operating cash flow target to a minimum of $9.5 billion, rising from the earlier $9 billion floor.
Prior to Wednesday’s session, shares had advanced only 1.7% year-to-date, underperforming the S&P 500’s 6% gain.
Aetna Shows Significant Medical Cost Management
The most impressive metric came from the Aetna insurance division’s medical benefit ratio, which registered 84.6%, substantially below analyst projections of 87.58% and marking an improvement from last year’s 87.3%.
This ratio reflects the percentage of premium income allocated to medical care expenses. Lower figures indicate stronger profitability retention. CFO Brian Newman attributed the enhancement to improved forecasting capabilities and disciplined cost management strategies.
Both UnitedHealth and Humana similarly exceeded analyst expectations on this measure during the first quarter, suggesting widespread operational improvements throughout the Medicare Advantage insurance sector.
The federal government announced in April a 2.48% average increase in 2027 Medicare Advantage reimbursement rates. Newman noted this adjustment remains insufficient to cover anticipated cost escalations next year, potentially requiring CVS to modify pricing structures or benefit offerings.
Health Services Revenue Grows While Retail Pharmacy Faces Pressure
The health services division, which includes the Caremark pharmacy benefit management operation, delivered an 11% revenue increase to $48.2 billion. The segment’s operating income reached $1.34 billion, aligning with analyst projections.
Newman credited a more profitable pharmaceutical product mix for strengthening Caremark’s financial performance. Leerink analyst Michael Cherny had previously identified achieving $1.3 billion in adjusted operating income for this segment as critical for rebuilding investor trust.
Pharmacy benefit managers continue facing scrutiny from legislators and regulatory bodies regarding drug pricing mechanisms. CVS currently has a pending FTC settlement concerning allegations that its PBM drove up insulin costs, claims the company disputes.
The company is also contesting Tennessee legislation that would prohibit PBMs from operating pharmacies within state boundaries. This bill has cleared the state legislature and awaits gubernatorial consideration.
The retail pharmacy division reported 5% revenue growth in 2025 following the acquisition of Rite Aid locations, which brought 9 million additional customers. However, the segment’s operating income declined 8.8% year-over-year during the first quarter.
CVS pointed to regulatory modifications affecting certain medication pricing, reduced cold and flu season activity, and weather-related disruptions — including snow-forced store closures — as headwinds impacting pharmacy operations.
